In the US, racial and ethnic disparities have been identified in multiple aspects of prostate cancer diagnosis and treatment.1,2,3,4 Specifically, Black patients are less likely to undergo appropriate prostate-specific antigen (PSA) screening,5 less likely to undergo intensive follow-up while on close monitoring for low-risk prostate cancer (ie, active surveillance),6,7 and less likely to undergo PSA surveillance after radical prostatectomy.8 Such variation in care contributes to increased mortality in Black patients diagnosed with prostate cancer.4,9. The gene discussed is KLK3; the disease is Familial prostate cancer.